Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8400293rdf:typepubmed:Citationlld:pubmed
pubmed-article:8400293lifeskim:mentionsumls-concept:C0032143lld:lifeskim
pubmed-article:8400293lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:8400293lifeskim:mentionsumls-concept:C0032140lld:lifeskim
pubmed-article:8400293lifeskim:mentionsumls-concept:C0005456lld:lifeskim
pubmed-article:8400293lifeskim:mentionsumls-concept:C0679932lld:lifeskim
pubmed-article:8400293pubmed:issue8lld:pubmed
pubmed-article:8400293pubmed:dateCreated1993-11-23lld:pubmed
pubmed-article:8400293pubmed:abstractTextCellular receptors for plasminogen and tissue plasminogen activator (t-PA) regulate plasminogen activation and cell-associated proteolytic activity. The characteristics of the interactions of both ligands with monocytes and monocytoid cell lines bear certain similarities, including affinity (kd approximately 1 mumol/L) capacity and susceptibility to carboxypeptidase treatment. Therefore, we have undertaken the present study to determine directly whether t-PA and plasminogen share common binding sites on cells. We found that recombinant human single-chain t-PA (rt-PA) could inhibit the binding of 125I-plasminogen to the cells and, conversely, plasminogen could inhibit 125I-rt-PA binding. This relationship was observed with 9 cell types, including both adherent cells and cells in suspension. In addition, under several conditions of cell treatment, plasminogen and t-PA receptor expression was modulated in parallel. Furthermore, molecules that have been implicated as candidate plasminogen receptors, gangliosides, and an alpha-enolase--related molecule, also interacted with t-PA. These results suggest that at least a component of the binding sites for plasminogen is shared with t-PA. Occupancy of these sites by either or both ligand(s) should result in arming the cells with the proteolytic activity of plasmin.lld:pubmed
pubmed-article:8400293pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:languageenglld:pubmed
pubmed-article:8400293pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8400293pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8400293pubmed:statusMEDLINElld:pubmed
pubmed-article:8400293pubmed:monthOctlld:pubmed
pubmed-article:8400293pubmed:issn0006-4971lld:pubmed
pubmed-article:8400293pubmed:authorpubmed-author:PlowE FEFlld:pubmed
pubmed-article:8400293pubmed:authorpubmed-author:FelezJJlld:pubmed
pubmed-article:8400293pubmed:authorpubmed-author:MilesL ALAlld:pubmed
pubmed-article:8400293pubmed:authorpubmed-author:ChanquiaC JCJlld:pubmed
pubmed-article:8400293pubmed:authorpubmed-author:FabregasPPlld:pubmed
pubmed-article:8400293pubmed:issnTypePrintlld:pubmed
pubmed-article:8400293pubmed:day15lld:pubmed
pubmed-article:8400293pubmed:volume82lld:pubmed
pubmed-article:8400293pubmed:ownerNLMlld:pubmed
pubmed-article:8400293pubmed:authorsCompleteYlld:pubmed
pubmed-article:8400293pubmed:pagination2433-41lld:pubmed
pubmed-article:8400293pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:meshHeadingpubmed-meshheading:8400293-...lld:pubmed
pubmed-article:8400293pubmed:year1993lld:pubmed
pubmed-article:8400293pubmed:articleTitleCompetition between plasminogen and tissue plasminogen activator for cellular binding sites.lld:pubmed
pubmed-article:8400293pubmed:affiliationInstitut De Recerca Oncologica, Hospital Duran i Reynals, Autovia de Castelldefels, L'Hospitalet de Llobregat, Barcelona, Spain.lld:pubmed
pubmed-article:8400293pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8400293pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8400293pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8400293lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8400293lld:pubmed